Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13550-017-0278-z http://scihub22266oqcxt.onion/10.1186/s13550-017-0278-z C5371538!5371538 !28357787     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28357787 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       EJNMMI+Res 2017 ; 7 (1 ): 29 Nephropedia Template TP {{tp|p=28357787 |t=2017. Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of (99m)Tc-sestamibi SPECT/CT |pdf=|usr=}}{{28357787 }} gab.com Text Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of (99m)Tc-sestamibi SPECT/CT JO: EJNMMI Res http://www.kidney.de/pget.php?&tw=1&pmid=28357787 #FOAvip BACKGROUND: Despite the progress in the quality of multiphasic CT and MRI scans, it is still difficult to fully characterize a solid kidney lesion. Approximately 10% of all solid renal tumours turn out to be oncocytomas. In actual clinical practice, this is verified only following unnecessary surgery or a renal biopsy/ablation. The objective of our pilot study examines whether (99m)Tc-sestamibi SPECT/CT can play a crucial role in the characterization of solid renal neoplasms and the differentiation of oncocytomas from renal cell carcinomas. The study included 27 patients identified with 31 solid renal lesions. All patients were discussed in a multidisciplinary conference, and a decision for surgery or biopsy was taken. Prior to invasive procedures, patients underwent a SPECT/CT with (99m)Tc-sestamibi. Visual evaluation was performed, and any focal (99m)Tc-sestamibi uptake detected on SPECT in the localisation of tumour was considered as positive. RESULTS: Eleven out of 12 oncocytomas (91.6%) displayed positive uptake of (99m)Tc-sestamibi. Three hybrid tumours (mixed-type oncocytoma and chromophobe renal cancer) were positive on SPECT/CT. One papillary renal cell carcinoma had a slight uptake of (99m)Tc-sestamibi. The remaining 11 renal cell carcinomas were sestamibi negative. CONCLUSIONS: Differentiation of benign renal oncocytomas from renal cell carcinomas seems very promising on (99m)Tc-sestamibi SPECT/CT examination. Additional supplement to visual evaluation, i.e. quantitative tools, should be sought for an accurate estimate of biological behaviour and hence a secure diagnosis. Twit Text FOAVip Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of (99m)Tc-sestamibi SPECT/CT ????EJNMMI Res http://www.kidney.de/pget.php?&tw=1&pmid=28357787 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28357787 #FOAvip English Wikipedia <ref>{{Cite pmid|28357787 }}</ref> Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of (99m)Tc-sestamibi SPECT/CT #MMPMID28357787 Tzortzakakis A ; Gustafsson O ; Karlsson M ; Ekström-Ehn L ; Ghaffarpour R ; Axelsson R EJNMMI Res 2017[Dec]; 7 (1 ): 29 PMID28357787 show ga BACKGROUND: Despite the progress in the quality of multiphasic CT and MRI scans, it is still difficult to fully characterize a solid kidney lesion. Approximately 10% of all solid renal tumours turn out to be oncocytomas. In actual clinical practice, this is verified only following unnecessary surgery or a renal biopsy/ablation. The objective of our pilot study examines whether (99m)Tc-sestamibi SPECT/CT can play a crucial role in the characterization of solid renal neoplasms and the differentiation of oncocytomas from renal cell carcinomas. The study included 27 patients identified with 31 solid renal lesions. All patients were discussed in a multidisciplinary conference, and a decision for surgery or biopsy was taken. Prior to invasive procedures, patients underwent a SPECT/CT with (99m)Tc-sestamibi. Visual evaluation was performed, and any focal (99m)Tc-sestamibi uptake detected on SPECT in the localisation of tumour was considered as positive. RESULTS: Eleven out of 12 oncocytomas (91.6%) displayed positive uptake of (99m)Tc-sestamibi. Three hybrid tumours (mixed-type oncocytoma and chromophobe renal cancer) were positive on SPECT/CT. One papillary renal cell carcinoma had a slight uptake of (99m)Tc-sestamibi. The remaining 11 renal cell carcinomas were sestamibi negative. CONCLUSIONS: Differentiation of benign renal oncocytomas from renal cell carcinomas seems very promising on (99m)Tc-sestamibi SPECT/CT examination. Additional supplement to visual evaluation, i.e. quantitative tools, should be sought for an accurate estimate of biological behaviour and hence a secure diagnosis. ?Visual evaluation and differentiation of renal oncocytomas from renal (epmc).pdf DeepDyve Pubget Overpricing